

Epigenetic changes in cancer

Manel Esteller

Address: Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), 08908 L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain

Email: mesteller@idibell.cat

F1000 Biology Reports 2011, **3**:9 (doi:10.3410/B3-9)

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/legalcode>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. You may not use this work for commercial purposes.

The electronic version of this article is the complete one and can be found at: <http://f1000.com/reports/b/3/9>

Abstract

Interest in epigenetics is now booming in all the biomedical fields. Initially, interest was sparked within the field of cancer research with the finding of global DNA hypomethylation events in the 1980s, followed by the CpG island hypermethylation of tumor suppressor genes in the 1990s and the approval of DNA demethylating drugs and histone deacetylase inhibitors in the 2000s. For transformed cells, the arena is also expanding to include the wide spectrum of histone modification changes and the interaction with noncoding RNAs. What lies ahead is even more exciting, with the imminent completion of many human cancer epigenomes that will form the basis of better biomarkers and epigenetic drugs.

Epigenetic changes in cancer

Much of the current hype in epigenetics stems from the recognition of its role in human cancer. Yet, intriguingly, the first epigenetic change in human tumors—global genomic DNA hypomethylation—was reported way back in the early 1980s, at about the same time the first genetic mutation in an oncogene was discovered [1]. So why the delay in recognizing the importance of epigenetics in cancer?

In the 1980s, epigenetics was a fledgling discipline, hampered by methodological limitations, while genetic knowledge of cancer was expanding exponentially. By the mid-1990s, however, classical tumor suppressor genes, such as *p16^{INK4a}*, *hMLH1*, and *VHL* [2], were shown to undergo a specific epigenetic hit (the inactivation of gene expression by CpG island hypermethylation), resulting in a major acceleration in the field. We now know that so-called epigenetic changes explain many hallmark features of malignant disease: these genes are deregulated not at the DNA level but at the complexly packaged chromatin level, which ultimately results in cell dysfunction.

Epigenetics may be important for the cancer field, but what does the term really mean? Truth be told, it has

many definitions, which have changed over the years as our knowledge has changed. Researchers studying this discipline recognize how bewildering such a nebulous term can be to nonexperts, and they get together from time to time to put forward better explanations and nomenclatures, but they usually come up empty-handed, or with recommendations that people do not remember. Thus, we have to go back to the classics. Waddington defined epigenetics in 1939 as “the causal interactions between genes and their products, which bring the phenotype into being” [3]. Adrian Bird redefined the term as “the structural adaptation of chromosomal regions so as to register, signal or perpetuate altered activity states” [4]. I prefer a more concrete definition: the inheritance of patterns of DNA and RNA activity that do not depend on the naked nucleotide sequence. By “inheritance,” I mean a memory of such activity transmitted from one cell generation to the next (through mitosis), or from one organismal generation to the next during meiosis. Meiotic inheritance is perhaps more provocative, as there is still scant direct evidence of epigenetic inheritance from one generation to the next in humans, but more abundant and robust data do exist in plants [5] and even mice [6]. However, genomic imprinting is a good example in

humans: when it goes awry it can lead to diseases such as Prader-Willi syndrome.

Epigenetics today is not a purely speculative subject, as it was in Waddington's time; it is based on a rapidly growing understanding of the chemical modifications that our genome and its regulatory proteins (the components of chromatin) undergo to control its functions. There are many modes of epigenetic control, including nucleosome positioning and noncoding-RNA-mediated regulation of gene expression (such as micro-RNAs). Nucleosome positioning refers to the constraints nucleosomes put on the DNA wrapped around their histone core, often affecting the accessibility of transcription factors and hence their ability to transcribe a gene. The best-studied epigenetic marks, however, are DNA methylation and histone modifications.

In humans, DNA methylation typically occurs at the cytosine base of DNA, within CpG dinucleotides. What is interesting is the existence of CpG-rich regions—"CpG islands"—that are associated with the 5'-end regulatory regions of almost all housekeeping genes as well as with half of tissue-specific genes. When these promoter CpG islands are methylated, the associated genes tend to be transcriptionally inactive. Indeed, the correct expression of many tissue-specific, germline-specific, imprinted, and X chromosome-inactivated (in females) genes, as well as that of repetitive genomic sequences, relies largely on DNA methylation.

The other critical epigenetic marks are chemical modifications of the N-terminal tails of histone proteins. Histones, once considered mere DNA-packaging proteins, regulate the underlying DNA sequences through complex post-translational modifications such as lysine acetylation, arginine and lysine methylation, or serine phosphorylation. It has been proposed that distinct combinations of modifications presented on histone tails form a "histone code" that regulates gene activity. This has prompted vigorous debate, with dissenters arguing that patterns of histone modification cannot really constitute a "code" that adheres to hard and fast rules, as in the case of the triplet codon rule that translates transcribed DNA sequences into protein. Nonetheless, for many epigenetic researchers this is a helpful perspective in trying to make sense of the numerous combinations of histone tail modifications.

A central question in epigenetics is how one genotype can give rise to different phenotypes. In an individual, it is clear that all tissues have the same genome, yet activity varies vastly from cell to cell. We now know

that this is largely because the right epigenetic marks instruct specialized programs that distinguish, for example, a retinal cell from a myocyte, a T lymphocyte, or a skin epithelial cell sharing the same DNA sequence. Thus, defects in cloned animals could be explained by our inability to replicate exactly the epigenetic program that steered the course of development in the donor individual. Similarly, defects in babies conceived by *in vitro* fertilization could be attributable to imprinting variations leading to imprinted disorders. DNA methylation and histone modifications even may explain the different penetrance of diseases displayed in monozygotic twins, as first reported in one of our papers [7]. This work has occasionally prompted inquiries from police or lawyers, asking whether we can assist in differentiating one identical twin from his or her sibling in court cases.

An epigenetic mutant-mouse strain illustrates how even diet can alter phenotype via an epigenetic mechanism: a DNA methylation variant mouse (agouti strain) changes fur color depending on the levels of methyl donors obtained through its diet, and the trait is heritable to the next generation [8]. These discoveries actually restore some credibility to Lamarck's discredited hypothesis of the inheritance of acquired traits, which has long been regarded as the antithesis of neo-Darwinian genetic theory.

Many cancer scientists have gotten aboard the epigenetic bandwagon since new, user-friendly PCR- and sequencing-based technologies have been developed. The list of tumor suppressor genes shown to undergo epigenetic inactivation has consequently grown long in the last few years. And in addition to the candidate-gene approach, array-based techniques have also detected on the order of 300 epigenetically modified genes in cancers, using expression arrays combined with DNA demethylating treatments or direct DNA methylation microarrays [9] (Figure 1).

Epigenetic disruption of the "dark genome"—the 90% of our genome that does not code for messenger RNA and proteins—is a very exciting finding that looks to be extremely relevant in cancer etiology. MicroRNAs with growth-inhibitory functions, such as miR-124a and miR-34b/c, undergo epigenetic inactivation because the sequences surrounding their respective transcription start sites become hypermethylated [10,11]. Overall, the emerging picture shows that distinctive cancer-associated patterns of CpG island hypermethylation are tumor type-specific and contribute decisively to the origin and development of human cancer.


Figure 1. Cancer and the genome

CANCER AND THE EPIGENOME

In cancer cells the epigenetic landscape is highly altered. Hypermethylation of certain stretches of DNA is the most well-studied epigenetic modification in cancer, and each tumor type has its own specific pattern. Histone modifications also occur, as does remodeling of chromatin. And disruption of noncoding RNA sequences, the so-called "dark genome," that code for micro-RNAs also seems to play a role in how cancer originates and spreads.

EPIGENETIC MARKS IN NORMAL CELLS

A CpG island consists of a stretch of some 300 to 3,000 DNA bases where clusters of cytosine and guanine dinucleotides make up about half the sequence ①. More than 60% of these islands are associated with the promoter regions of genes and are not methylated in genes that are actively transcribed. Located some 2 kb from these promoter regions are stretches of DNA that are not quite so rich in CpG, known as CpG shores ②. Methylation of these cytosines results in gene inactivation and is associated with structural changes in chromatin that occur during differentiation and chromosome imprinting in developing embryos. Inactive chromatin consists of DNA tightly wrapped around a core of eight histones whose projecting tails are modified with various covalent marks ③. Protein complexes associate with chromatin and control gene activation or repression by adding or removing marks such as methyl and acetyl groups to histones or methyl groups to cytosine bases in the DNA chain ④.



Besides providing a better understanding of cancer at the molecular level, what hope does epigenetics bring to applied cancer research? Table 1 provides examples in this area. Epigenetics has already revealed useful diagnostic biomarkers (*GSTP1* in prostate cancer) and prognostic biomarkers. This has been an eye-opener for oncologists and hematologists, as transformed cells with specific hypermethylation patterns on certain genes have turned out to be reliable biomarkers for particular types and stages of cancer. The best example is the aberrant DNA methylation of the gene that encodes glutathione S-transferase P (*GSTP1*), almost exclusively observed in prostate cancer, which seems to be a valuable biomarker for indicating the disease and a malignant transformation prognosis in older males with high levels of prostate-specific antigen. The fact that these epigenetic markers can be detected in all types of biological fluids and biopsies [12] in a background of many normal cells makes them very promising tools for disease screening and monitoring. With the advent of genome-wide methodologies, researchers are currently working on typing whole aberrant DNA methylation fingerprints. Such expression microarray signatures could, in the future, serve as potential prognostic tools, which could indicate time to progression or overall survival. This research is being done in breast cancer; however, clinical application is still years away.

Another invaluable use of epigenetic markers is in the prediction of responses to particular chemotherapy agents. The proof of principle was provided by the DNA repair enzyme MGMT (*O*⁶-methylguanine-DNA methyltransferase), which, when the gene's promoter region was hypermethylated at its CpG island, predicted that treatment with alkylating agents such as carmustine or temozolomide in gliomas would generate a good therapeutic response [13]. This is because MGMT repairs the lesions caused by these drugs, and if the enzyme is not there, as in cancer cells, the DNA damage is permanent and the cell dies.

Potential treatment strategies for breast cancer in carriers of mutated *BRCA1*, the classical tumor suppressor gene, have been boosted by pharmacoepigenetics—the study of epigenetic variants that affect the response to drug therapies. The population of mutated *BRCA1* carriers is low; thus, the discovery that *BRCA1* can exist as an epimutant when hypermethylated has increased the pool of individuals affected by this high-risk, cancer-causing aberration. This is accelerating the development of the use of PARP (poly [ADP-ribose] polymerase) inhibitors, known to have a good response in *BRCA1* tumors [14].

Histone modification patterns are also altered in human tumors. In particular, levels of histone H4 lysine 20 trimethylation (H4K20me3) and histone H4 lysine 16 monoacetylation (H4K16ac) are severely disturbed in cancer cells [15] both globally and at particular loci. Comparing absolute results between laboratories, however, is proving troublesome, since the central technique—chromatin immunoprecipitation—has more interindividual and interlaboratory variation than the usual DNA methylation assays, and depends largely on the quality of the antibodies used. Thus the community is not yet at a stage where it can use altered histone modification profiles found in cancer as biomarkers. Researchers are, however, finding an increasing number of histone modifier genes disrupted in many cancers, opening the door to small-molecule drug development targeted against aberrant histone modifiers. This is particularly applicable to hematological malignancies and sarcomas, in which translocations that generate fusion proteins involving histone methyltransferases and histone acetyltransferases are common [16]. The approach is also relevant for the gene amplification of histone demethylases in solid tumors.

A strong selling point for epigenetic cancer research is the fact that epigenetically inactivated genes can conceivably be reactivated with the right drugs, while genetic changes are irreversible. To date, a few

Table 1. Using epigenetics to fight cancer

Area	Examines	Information	Example
Diagnosis	Epigenetic markers	<ul style="list-style-type: none"> DNA methylation patterns Histone marks 	<i>GSTP1</i> gene in prostate cancer
Prognosis	Changes in epigenetic markers over time	<ul style="list-style-type: none"> Comparative patterns 	p16 ^{INK4a} gene in colon cancer
Pharmacogenetics	Methylation and gene expression profiles	<ul style="list-style-type: none"> Fuller picture to predict drug response 	<i>MGMT</i> gene in glioma
Drug targets	<ul style="list-style-type: none"> Epigenetic marks (DNA/histones) Chromatin-modifying proteins 	<ul style="list-style-type: none"> Add/read/remove epigenetic marks Epigenetic marks 	5-azacytidine

GSTP1, glutathione S-transferase P; *MGMT*, *O*⁶-methylguanine-DNA methyltransferase.

pharmacological compounds directed toward epigenetic enzymes have shown promise in treating leukemias and lymphoma. These include DNA demethylating agents (5-azacytidine and 5-aza-2'-deoxycytidine) and histone deacetylase inhibitors (i.e., suberoyl anilide bishydroxamide [SAHA] [17]). Although their exact antitumor mechanism has not been completely elucidated, most of them cause programmed cell death and, at current doses, show limited toxicity in patients. The translation of these advances in hematological malignancies to solid tumors is slow, and it will be critical for ongoing studies to identify markers of good response to epigenetic drugs. New compounds continue to be developed in preclinical research, targeting other histone modifiers, such as the class of histone deacetylases called sirtuins. Researchers are on the lookout for more specific DNA demethylating agents that do not change normal DNA methylation.

Cancer epigenetics is an exciting field as we continue to discover new types of epigenetic marks and levels of epigenetic control. Recent examples include the newly discovered 5-hydroxymethylcytosine modification; the chemical modification of RNA; the existence of important regulatory regions outside the minimal promoter, such as CpG island shores and enhancers; the role of chromatin remodeling factors that move nucleosomes around using ATP; and, most importantly, the epigenetic layers present in the noncoding RNA genome. The widespread use of high-throughput technologies will in a short time, I am sure, produce comprehensive cancer epigenomes to study and employ in the better management of oncology patients. Glimpses can already be seen in the publication of, for example, small-epigenome characterization [18] and whole-genome DNA methylation analyses [19].

Abbreviations

BRCA1, breast cancer 1, early onset; GSTP1, glutathione S-transferase P; MGMT, O⁶-methylguanine-DNA methyltransferase; PCR, polymerase chain reaction.

Competing interests

The author declares that he has no competing interests.

References

1. Feinberg AP, Vogelstein B: **Hypomethylation distinguishes genes of some human cancers from their normal counterparts.** *Nature* 1983, **301**:89-92.
 2. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarr JR, Linehan WM, Baylin SB: **Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma.** *PNAS* 1994, **91**:9700-04.
 3. Waddington CH: **The epigenotype.** *Endeavour* 1942, **1**:18-20.
 4. Bird A: **DNA methylation patterns and epigenetic memory.** *Genes Dev* 2002, **16**:6-21.
 5. Teixeira FK, Heredia F, Sarazin A, Roudier F, Boccard M, Ciaudo C, Cruaud C, Poulain J, Berdasco M, Fraga MF, Voinnet O, Wincker P, Esteller M, Colot V: **A role for RNAi in the selective correction of DNA methylation defects.** *Science* 2009, **323**:1600-4.
 6. Morgan HD, Sutherland HG, Martin DI, Whitelaw E: **Epigenetic inheritance at the agouti locus in the mouse.** *Nat Genet* 1999, **23**:314-8.
 7. Fraga MF, Ballestar E, Paz MF, Ropero S, Setien F, Ballestar ML, Heine-Suñer D, Cigudosa JC, Urioste M, Benitez J, Boix-Chornet M, Sanchez-Aguilera A, Ling C, Carlsson E, Poulsen P, Vaag A, Stephan Z, Spector TD, Wu YZ, Plass C, Esteller M: **Epigenetic differences arise during the lifetime of monozygotic twins.** *PNAS* 2005, **102**:10604-09.
- F1000 Factor 9
 Evaluated by Alain Ghysen 15 Jul 2005, Charles Auffray 27 Jul 2005, Stephen Scherer 04 Aug 2005, Thomas Jenuwein 14 Feb 2006
8. Wolff GL, Kodell RL, Moore SR, Cooney CA: **Maternal epigenetics and methyl supplements affect agouti gene expression in Avy/a mice.** *FASEB J* 1998, **12**:949-57.
 9. Berdasco M, Esteller M: **Aberrant epigenetic landscape in cancer: how cellular identity goes awry.** *Dev Cell* 2010, **19**:698-711.
 10. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA, Jones PA: **Specific activation of microRNA-127 with down-regulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells.** *Cancer Cell* 2006, **9**:435-43.
 11. Lujambio A, Calin GA, Villanueva A, Ropero S, Sánchez-Céspedes M, Blanco D, Montuenga LM, Rossi S, Nicoloso MS, Fallar WJ, Gallagher WM, Eccles SA, Croce CM, Esteller M: **A microRNA DNA methylation signature for human cancer metastasis.** *PNAS* 2008, **105**:13556-61.
 12. Esteller M, Sanchez-Céspedes M, Rosell R, Sidransky D, Baylin SB, Herman JG: **Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients.** *Cancer Res* 1999, **59**:67-70.
 13. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG: **Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.** *N Engl J Med* 2000, **343**:1350-54.
 14. Veeck J, Ropero S, Setien F, Gonzalez-Suarez E, Osorio A, Benitez J, Herman JG, Esteller M: **BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors.** *J Clin Oncol* 2010, **28**:e563-64.
 15. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bonaldi T, Haydon C, Ropero S, Petrie K, Iyer NG, Pérez-Rosado A, Calvo E, Lopez JA, Cano A, Calasanz MJ, Colomer D, Piris MA, Ahn N, Imhof A, Caldas C, Jenuwein T, Esteller M: **Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer.** *Nat Genet* 2005, **37**:391-400.
- F1000 Factor 8
 Evaluated by Genevieve Almouzni 14 Apr 2005
16. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bonaldi T, Haydon C, Ropero S, Petrie K, Iyer NG, Pérez-Rosado A, Calvo E, Lopez JA, Cano A, Calasanz MJ, Colomer D, Piris MA, Ahn N, Imhof A, Caldas C, Jenuwein T, Esteller M: **Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer.** *Nat Genet* 2005, **37**:391-400.
 17. Marks PA, Breslow R: **Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug.** *Nat Biotechnol* 2007, **25**:84-90.
 18. Fernandez AF, Rosales C, Lopez-Nieva P, Graña O, Ballestar E, Ropero S, Espada J, Melo SA, Lujambio A, Fraga MF, Pino I, Javierre B, Carmona FJ, Acquadro F, Steenbergen RD, Snijders PJ, Meijer CJ, Pineau P, Dejean A, Lloveras B, Capella G, Quer J, Buti M, Esteban JI,

Allende H, Rodriguez-Frias F, Castellsague X, Minarovits J, Ponce J, Capello D, *et al.*: **The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer.** *Genome Res* 2009, **19**:438-51.

19. Lister R, Pelizzola M, Dowen RH, Hawkins RD, Hon G, Tonti-Filippini J, Nery JR, Lee L, Ye Z, Ngo QM, Edsall L, Antosiewicz-

Bourget J, Stewart R, Ruotti V, Millar AH, Thomson JA, Ren B, Ecker JR: **Human DNA methylomes at base resolution show widespread epigenomic differences.** *Nature* 2009, **462**:315-22.

F1000 Factor 15

Evaluated by Hongjun Song 21 Oct 2009